INTERVIEW

Interview: Understanding the Impact of USP<382> on Primary Packaging Development

Laure-Hélène Guillemot discusses the new USP <382> chapter coming into force on December 1st, 2025, which will significantly transform functional testing protocols for pharmaceutical companies.

Interview: PDA Miniverse and Trends in Injectable Drug Delivery

In this exclusive interview, Mathias Romacker and Evan Edwards talk with ONdrugDelivery’s Guy Furness about the upcoming inaugural PDA Miniverse conference in Indianapolis, and the topics and trends currently being felt across the injectable drug delivery industry.

A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors

Dr Patrick Anquetil

Portal Instruments

A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors

In this exclusive interview with ONdrugDelivery’s Guy Furness, Dr Patrick Anquetil offers insight into the extensive waste involved in the self-injection market. He explains how pivoting from a model focused on fully disposable devices to reusable electromechanical autoinjectors could offer a more sustainable and cost-effective path forward.

The Transition to Lower-Global-Warming-Potential Propellants in pMDIs

The Transition to Lower-Global-Warming-Potential Propellants in pMDIs

Aptar Pharma’s Chris Baron discusses how the company has developed a new metering valve technology platform – ZEN30 Futurity™ – that is compatible with leading lower-GWP propellants. By collaborating with drug developers, regulators and the pMDI supply chain, Aptar Pharma aims to support the reduction of the CO₂ footprint of pMDIs while ensuring that the pharmaceutical industry’s strict regulatory requirements are met or exceeded.

Interview: Sustainability at the Heart of Aptar Pharma’s Expansion

Audrey Chardonnet

Interview: Sustainability at the Heart of Aptar Pharma’s Expansion

Audrey Chardonnet discusses the centrality of sustainability to Aptar Pharma’s expansion strategy, going into detail on how, by improving its practices and investing in its infrastructure, the company works towards reducing the environmental impact of injectable drug delivery solutions manufacturing.

Interview: Pharmapack Start-up Spotlight: InnoMedica Accelerating Trials with Novel Nanoparticle Filling

Pascal Halbherr

Interview: Pharmapack Start-up Spotlight: InnoMedica Accelerating Trials with Novel Nanoparticle Filling

Pascal Halbherr discusses the InnoMedica's innovative nanocarrier filling technology platform, its impact on biotech and drug delivery, and the company’s bold vision for the future. InnoMedica, a Swiss biotech, is one of the 28 early-stage companies presenting cutting-edge innovations in Pharmapack Europe 2025’s Start-up Market.

INTERVIEW: PUREHALE<sup>®</sup> AND THE FUTURE OF FINE MIST DISPENSERS FOR UPPER AIRWAY TREATMENTS

INTERVIEW: PUREHALE^® AND THE FUTURE OF FINE MIST DISPENSERS FOR UPPER AIRWAY TREATMENTS

Julien Storz and Giulia Mueller discuss the latest trends and treatment options available for upper airway conditions, along with the many benefits offered by Aptar Pharma’s advanced PureHale^® systems to manufacturers.

Pharmapack Preview: An INTERVIEW with ALASTAIR WILLOUGHBY

Alastair Willoughby

Team Consulting

Pharmapack Preview: An INTERVIEW with ALASTAIR WILLOUGHBY

CPHI Milan this year included a key discussion led by Team Consulting’s Alastair Willoughby on “Understanding the Problem of Decarbonisation in Drug Delivery”; one of the industry’s critical challenges. These themes will be discussed in greater depth at Pharmapack Europe in Paris in January.

INTERVIEW with Scott Ariagno, EdgeOne Medical

EdgeOne Medical

INTERVIEW with Scott Ariagno, EdgeOne Medical

Scott Ariagno talks exclusively with ONdrugDelivery's Guy Furness about the role that contract development organisations play in the drug delivery industry ecosystem and how independent expertise can enable companies like EdgeOne Medical to troubleshoot and accelerate product development.

ROUNDTABLE: DISCUSSION ON ANTI-OBESITY TREATMENTS

ROUNDTABLE: DISCUSSION ON ANTI-OBESITY TREATMENTS

Stephen M Perry, Mathias Romacker and Andreas Schneider tackle the subject of GLP-1s and related obesity-targeted injectable therapeutics and the enormous impact they are having and are expected still to have on drug delivery and the wider pharmaceutical sector.

Interview with Bespak’s Louise Righton & Benedicta Bakpa

Interview with Bespak’s Louise Righton & Benedicta Bakpa

An increasing global incidence of respiratory diseases, such as asthma and COPD, is driving demand for therapies. Simultaneously, greenhouse gas emissions continue to rise, so the pharma industry must consider how to produce much-needed nasally delivered and orally inhaled medicines whilst minimising environmental impact. Louise Righton and Benedicta Bakpa discuss the many different aspects involved in driving sustainability in inhaled drug delivery – and the next steps.

INTERVIEW with GLENN SVEDBERG

INTERVIEW with GLENN SVEDBERG

Glenn Svedberg engages in a wide-ranging discussion around the role and importance of sustainability in the drug delivery industry, and how Nolato Group has approached implementing this critical aspect of the modern industry landscape. Mr Svedberg considers how sustainability factors play into the relationship between CDMOs like Nolato and pharma companies, the importance of materials and how to drive forward sustainability goals within pharma and drug delivery.

Interview with DEAN MINNOCK

Dr Dean Minnock

Interview with DEAN MINNOCK

Guy Furness and Dean Minnock discuss Innovation Zed’s unique origin story and digital connectivity add-on for injection pens. They dive into the value of digital ecosystems in the drug delivery industry and look towards the future as the company prepares to launch its third-generation add-on technology – DOSE.

Interview with Eric Leven, Rip Road

Interview with Eric Leven, Rip Road

Guy Furness and Eric Leven discuss Rip Road’s work with SaMD applications, including the company's customisable platform for delivery device companion apps. Leven shares his thoughts on the potential of connectivity to enhance the patient experience of biologic therapies, based on years working in the digital space, as well as how far connected drug delivery has come and how far it has yet to go.

INTERVIEW: THE BENEFITS OF BEING AN EARLY ADOPTER OF SUSTAINABILITY PRINCIPLES

INTERVIEW: THE BENEFITS OF BEING AN EARLY ADOPTER OF SUSTAINABILITY PRINCIPLES

Reto Jost and Gabriel Kalbermatter talk exclusively with ONdrugDelivery's Guy Furness, discussing the progress Ypsomed has made in advancing its sustainability agenda, particularly the implementation of its ecodesign guideline, the benefits of being an early adopter of sustainability principles, how YpsoMate 5.5 mL has been designed from the ground up with sustainability in mind and where sustainability considerations currently fit into the wider pharma industry.

INTERVIEW with Dora Rio, Head of Sustainability, SHL Medical

INTERVIEW with Dora Rio, Head of Sustainability, SHL Medical

Dora Rio discusses various aspects of SHL's approach to sustainability, including how it interacts with other players up and down the value chain, whether reusable or single-use devices are more sustainable and how SHL addresses sustainability concerns beyond CO₂.

SUSTAINABILITY PROGRAMMES: EVERY STEP COUNTS

SUSTAINABILITY PROGRAMMES: EVERY STEP COUNTS

Henryk Badack shares insights into the current state of sustainability in the pharma and biotech industry, how sustainability commitments vary between organisations and what companies can do to develop sustainability strategies that will last.

Interview: EXPLORING NASAL CASTS IN NASAL DRUG DEVELOPMENT

Interview: EXPLORING NASAL CASTS IN NASAL DRUG DEVELOPMENT

Julie Suman discusses nasal casts, their development, applications and significance for nasal drug product development.

Interview with Sandy Munro, Vectura

Interview with Sandy Munro, Vectura

In this exclusive interview with ONdrugDelivery’s Guy Furness, Sandy Munro, PhD, of Vectura discusses his extensive career, focused on respiratory drug delivery. He shares his insights into current trends within the industry, including the growth of biologics, systemic delivery via inhalation, the potential of mesh nebulisers and connectivity in clinical trials.

INTERVIEW: UNITHER PHARMACEUTICALS’ INNOVATIVE APPROACH TO OPHTHALMIC MANUFACTURING

Unither Pharmaceuticals

INTERVIEW: UNITHER PHARMACEUTICALS’ INNOVATIVE APPROACH TO OPHTHALMIC MANUFACTURING

Natalia Servol shares insights into Unither Pharmaceutical’s preservative-free multidose technology. With a focus on addressing patient needs and meeting industry demands, the company offers a distinctive approach to sterile manufacturing in the ophthalmic sector.

Interview with Lilli Zakarija, EdgeOne Medical

EdgeOne Medical

Interview with Lilli Zakarija, EdgeOne Medical

Lilli Zakarija talks with Guy Furness about how EdgeOne Medical provides a critical service to companies undertaking drug delivery device development programmes, from small biotech start-ups all the way up to major pharmaceutical players. As part of this discussion, Ms Zakarija delves into the evolution of the drug delivery device industry over the past decades, some common pitfalls companies fall into during device development and what makes this sector such an exciting one to work in.

Interview with Alexandre Fontayne, Unither Pharmaceuticals

Dr Alexandre Fontayne

Unither Pharmaceuticals

Interview with Alexandre Fontayne, Unither Pharmaceuticals

Guy Furness and Alexandre Fontayne discusses Unither Pharmaceuticals' EuroJect^® injection device, based on the company’s extensive experience with blow-fill-seal technology. Mr Fontayne covers the advantages of EuroJect^® compared with traditional glass syringes and multidose vials, as well as touching on where Unither sees EuroJect^® having an impact in the market

A SYMBIOTIC RELATIONSHIP BETWEEN DRUG DELIVERY DEVICE SYSTEMS AND PHARMA

Dr Troels Keldmann

A SYMBIOTIC RELATIONSHIP BETWEEN DRUG DELIVERY DEVICE SYSTEMS AND PHARMA

Troels Keldmann discusses the significance of the drug delivery industry, its relationship to pharma, the challenges it faces and how the pharma industry is shaping the drug delivery device field.

INTERVIEW with Jeff Henderson

INTERVIEW with Jeff Henderson

Jeff Henderson discusses the practice of outsourcing within the pharmaceutical industry. He considers factors that pharma and biopharma companies should consider when determining whether or not to outsource to a CDMO and many of the advantages that outsourcing can offer, especially to small- and medium-sized companies.

Interview with Claire Raynal-Olive & Pierre-Yves Favennec

Claire Raynal-Olive

Interview with Claire Raynal-Olive & Pierre-Yves Favennec

Claire Raynal-Olive and Pierre-Yves Favennec discuss the strategy and objectives of Aptar Pharma’s expansion programme of its global rubber component manufacturing, implementing advanced technology, increased capacity and local-for-local manufacturing capability.

AUTOMATING ASSEMBLY TO EXPEDITE TIME-TO-MARKET

INDUSTRIALISATION

Dr Dave Seaward

AUTOMATING ASSEMBLY TO EXPEDITE TIME-TO-MARKET

Dave Seaward discusses how 3P innovation takes a holistic approach to solving the technical challenges encountered by its clients and looks for opportunities to enhance the final product, enable efficient processing and support commercially viable manufacturing.

1
2
3
4
Next

Top